Human Leukocyte Antigen Association Study Reveals DRB1*04:02 Effects Additional to DRB1*07:01 in Anti-LGI1 Encephalitis
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received August 23, 2021
- Accepted in final form December 27, 2021
- First Published February 3, 2022.
Author Disclosures
- Vicente Peris Sempere, MSc* (vsempereperis{at}gmail.com),
- Sergio Muñiz-Castrillo, MD, PhD* (ext-sergio.muniz{at}chu-lyon.fr),
- Aditya Ambati, PhD (ambati{at}stanford.edu),
- Sophie Binks, MD (sophie.binks{at}st-hildas.ox.ac.uk),
- Anne-Laurie Pinto, MSc (anne-laurie.pinto{at}chu-lyon.fr),
- Veronique Rogemond, PhD (veronique.rogemond{at}chu-lyon.fr),
- Sean J. Pittock, MD (pittock.sean{at}mayo.edu),
- Divyanshu Dubey, MD (dubey.divyanshu{at}mayo.edu),
- Michael D. Geschwind, MD, PhD (michael.geschwind{at}ucsf.edu),
- Jeffrey Marc Gelfand, MD (jeffrey.gelfand{at}ucsf.edu),
- Sonam Dilwali, MD (sonam.dilwali{at}ucsf.edu),
- Soon-Tae Lee, MD, PhD (slee{at}snuh.org),
- Julian Knight, PhD (julian{at}well.ox.ac.uk),
- Katherine S. Elliott, PhD (kelliott{at}well.ox.ac.uk),
- Sarosh Irani, MD, PhD (sarosh.irani{at}ndcn.ox.ac.uk),
- Jérôme Honnorat, MD, PhD† (jerome.honnorat{at}chu-lyon.fr) and
- Emmanuel Mignot, MD, PhD†
- Vicente Peris Sempere, MSc* (vsempereperis{at}gmail.com),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Sergio Muñiz-Castrillo, MD, PhD* (ext-sergio.muniz{at}chu-lyon.fr),
- Aditya Ambati, PhD (ambati{at}stanford.edu),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Sophie Binks, MD (sophie.binks{at}st-hildas.ox.ac.uk),
NONE
NONE
NONE
NONE
SB is a co-applicant on a patent application entitled ÂDiagnostic Strategy to improve specificity of CASPR2 antibody detection (PCT/GB2019/051257).
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
SB is supported by the Wellcome Trust and has previously had salary support from the National Institute for Health Research NIHR).
SB holds grants from PetSavers and PetPlan charitable trust.
NONE
NONE
NONE
NONE
NONE
NONE
- Anne-Laurie Pinto, MSc (anne-laurie.pinto{at}chu-lyon.fr),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Veronique Rogemond, PhD (veronique.rogemond{at}chu-lyon.fr),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Sean J. Pittock, MD (pittock.sean{at}mayo.edu),
Alexion Pharmaceutical Advisory Board - Compensation to Mayo Clinic Medimmune/Viele Bio Advisory Board - Compensation to Mayo Clinic UCB pharmaceuticals - Personal compensation Hoffman/LaRoche - Personal compensation Roche/Genentech - Personal compensation
NONE
NONE
NONE
Dr. Pittock has a patent Patent# 8,889,102 (Application#12-678350) - Neuromyelitis Optica Autoantibodies as a Marker for Neoplasia issued, and a patent Patent# 9,891,219B2 (Application#12-573942) - Methods for Treating Neuromyelitis Optica (NMO) by Administration of Eculizumab to an individual that is Aquaporin-4 (AQP4)-IgG Autoantibody positive issued. Dr Pittock has a patent pending for GFAP, Septin-5, Kelch11 and MAP1B autoantibodies as biomarkers of neurological autoimmunity.
NONE
NONE
Dr. Pittock has provided consultation to Alexion Pharmaceuticals and Medimmune/Viela Bio but has received no personal fees or personal compensation for these consulting activities. All compensation for consulting activities is paid directly to Mayo Clinic. Dr. Pittock provided consultation to Astellas- Compensation to Mayo and personal compensation. Dr. Pittock received personal compensation for consultation services to UCB, Genentech, Sage Therapeutics, and Prime Therapeutics.
NONE
No activity to report. I am a salaried employee of Mayo Clinic and salary is fixed specialty dependent and not impacted by test volume or laboratory income.
NONE
Dr Pittock has received research funding from Grifols, Medimmune/Viela Bio, Alexion and the National Institute of Health (NIH).
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Divyanshu Dubey, MD (dubey.divyanshu{at}mayo.edu),
Dr. Divyanshu Dubey has attended UCB Advisory Board Meeting in Lyon, France on September 23, 2019. All compensation for consulting activities is paid directly to Mayo Clinic.
Dr. Dubey has consulted for UCB, Immunovant and Astellas pharmaceuticals. All compensation for consulting activities is paid directly to Mayo Clinic.
NONE
Dr. Dubey is on the editorial board of Journal of Clinical Medicine.
Dr. Dubey has patent pending for Klech like protein 11 and Leucine zipper 4 as a marker of neurological autoimmunity and germ cell tumors.
NONE
NONE
NONE
NONE
NONE
NONE
Dr. Dubey has received research support from Grifols pharmaceuticals.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Michael D. Geschwind, MD, PhD (michael.geschwind{at}ucsf.edu),
NONE
NONE
Speaking honorarium from American Academy of Neurology and Wolters Kluwer Health/AudioDigest.
Editorial board,
NONE
NONE
NONE
Serving or has served as a consultant Clarion consulting, Microvention Terumo, Bioscience Pharma Partners, LLC (BPP), Teledoc Health, Inc., First Thought Consulting, Ascel Health LLC, LifeSci Capital LLC for consulting, ClearView Healthcare Partners, Blade Therapeutics, Inc. Consulting as medical-legal expert and expert witness for MedConnect, Wallace & Millsap, LLC, and Maupin Cox Legoy LLC.
NONE
NONE
NONE
NONE
Research support from NIH/NIA R01 AG031189 PI 2013-2020, R56 AG055619-01A 2018-2019, R01AG062562 PI 2019-2024, Alliance Biosecure 2016-18.
NONE
Michael J. Homer Family Fund
NONE
NONE
NONE
NONE
NONE
NONE
- Jeffrey Marc Gelfand, MD (jeffrey.gelfand{at}ucsf.edu),
DSMB for a National Institutes of Aging funded study. Service on scientific advisory boards for Genentech/Roche.
NONE
NONE
Dr. Gelfand is on the editorial advisory board of Neurology: Neuroimmunology & Neuroinflammation. Dr. Gelfand's spouse is Editor-in-Chief of Headache and previously served on the editorial team of JAMA Neurology.
NONE
Dr. Gelfand's spouse has received honoraria from UpToDate.
NONE
Consulting for Biogen. His spouse has received prior consulting fees from Biohaven, Advanced Clinical, Theranica, and Satsuma.
NONE
NONE
NONE
Research support to University of California, San Francisco from Genentech/Roche and Vigil Neuroscience. His spouse has received grant support from Amgen.
NONE
NONE
PI of an Institutional Clinician Training Award from the National MS Society.
NONE
NONE
NONE
NONE
NONE
Dr. Gelfand has received compensation for medical-legal consulting as an expert witness.
- Sonam Dilwali, MD (sonam.dilwali{at}ucsf.edu),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Soon-Tae Lee, MD, PhD (slee{at}snuh.org),
advisory roles for Roche/Genentech, UCB, Ono Pharmaceuticals, Biofire Diagnostics, and Advanced Neural Technologies.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Julian Knight, PhD (julian{at}well.ox.ac.uk),
NONE
NONE
NONE
NONE
NONE
Human Genetic Diversity. Functional Consequences for Health and Disease. Oxford, Oxford University Press. 2009
NONE
NONE
NONE
NONE
NONE
Janssen
Medical Research Council, MR/V002503/1, Principal Investigator, 2020-2024
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Katherine S. Elliott, PhD (kelliott{at}well.ox.ac.uk),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Sarosh Irani, MD, PhD (sarosh.irani{at}ndcn.ox.ac.uk),
Encephalitis Society and Autoimmune Encephalitis Alliance (non-profit, charity). ADC therapeutics, Immunovant and UCB (commercial)
NONE
SRI has received honoraria for speaking at scientific conferences, including the Movement Disorder Society, Dublin Neuroimunology Symposium, Korean Encephalitis meeting and Bethel Epilepsy Symposium.
NONE
SRI receives royalties on patent application WO/2010/046716 entitled 'Neurological Autoimmune Disorders'. The patent has been licensed for the development of assays for LGI1 and other VGKC-complex antibodies.
NONE
NONE
1. Commercial. MedImmune Ltd. 2. ADCT 3. Minnetronix Neuro Inc 4. UCB Pharma 5. Medicolegal projects (various)
NONE
NONE
NONE
Commercial: SRI has received research funding from UCB, CSL Behring and ONO pharmaceuticals
S.R.I has received a NIHR fellowship, Department of Health, UK to fund his DPhil/PhD
SRI received funding support from a MRC Senior Clinical Fellowship, Wellcome Intermediate Clinical Fellowship, BMA Research Grants - Vera Down grant, the Fulbright UK-US commission and the MS society (2012-2013).
NONE
NONE
NONE
For VGKC-complex antibody patent, as described above. Royalties paid by OUI.
NONE
NONE
NONE
- Jérôme Honnorat, MD, PhD† (jerome.honnorat{at}chu-lyon.fr) and
- Emmanuel Mignot, MD, PhD†
Kleine-Levin Syndrome Foundation: Member, Medical Advisory Board Member(non for profit) Rythm/Dreem Inc., Scientific advisory board Member (for profit) Alerion Inc, Scientific Advisory board Member (for profit) Orexin/Inoxia, Scientific Advisory board Member (no for profit)
NONE
Jazz pharmaceuticals (for profit) Rythm/dreem (for profit) Inoxia/Orexia (for profit)
Journal Neuropsychopharmacology: Editorial Board Member, Journal Public Library of Sciences-Biology (PLoS-Biology): Editorial Board Member Journal Sleep Medicine: Editorial board member No compensation
NONE
Narcolepsy and Hypersomna, informa healthcare,Volume 220,2007
NONE
Jazz pharmaceuticals (commercial for profit) Rythm/dreem (commercial for profit) Orexin/Inoxia (commercial for profit)
Vox Media
NONE
I practice sleep medicine at Stanford Health care; as such I review and interpret sleep studies and MSLTs for my patients but I am not compensated by this practice directly
Airweave (commercial for profit) Apple (commercial for profit) Jazz Pharmaceuticals (commercial for profit) Merck (commercial for profit) Sunovion (commercial for profit) Takeda (commercial for profit)
1) Training grant in sleep and Genetics NIH/1T32HL110952 (Pack, Mignot, Chervin, Polotsky ÂPIÂs) 7/13/13 Â 6/30/18 Univ of Pennsylvania (Training grant) 2) KIR and HLA effects in CNS paraneoplastic syndromes and related neuroimmune conditions 1U01NS120885 (Mignot PI) 6/1/2020- 5/31/2025. Stanford University 3) Proteomic and Transcriptomic Biomarkers of Circadian Timing. 1R01HL148704-01A1 (Mignot, Czeisler PIs) 09/01/2020 Â 03/31/2024. Stanford University and BWH, Boston
NONE
NONE
Rythm/Dreem Inc., Scientific advisory board, stock ownership Alerion Inc, Scientific Advisory board, stock ownership Inoxia/Orexia, Scientific Advisory Board, stock ownership
NONE
NONE
NONE
NONE
NONE
- From the Stanford University Center for Sleep Sciences (V.P.S., A.A., and E.M.), Stanford University School of Medicine, Palo Alto, CA; French Reference Center for Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis (S.M.-C., A.-L.P., V.R., and J.H.), Hospices Civils de Lyon, Hôpital Neurologique; Synatac Team (S.M.-C., A.-L.P., V.R., and J.H.), NeuroMyoGene Institute, INSERM U1217/CNRS UMR5310, Université Claude Bernard Lyon 1, Université de Lyon, France; Oxford Autoimmune Neurology Group (S.B. and S.I.), Nuffield Department of Clinical Neurosciences, University of Oxford; Department of Neurology (S.B. and S.I.), John Radcliffe Hospital, Oxford, United Kingdom; Department of Laboratory Medicine and Pathology (S.J.P. and D.D.), and Department of Neurology (S.J.P. and D.D.), Mayo Clinic, Rochester, MN; Department of Neurology (M.D.G., J.M.G., and S.D.), University of California, San Francisco; Department of Neurology (S.-T.L.), Seoul National University Hospital, South Korea; and Wellcome Centre for Human Genetics (J.K. and K.S.E.), Nuffield Department of Medicine, University of Oxford, United Kingdom.
- Correspondence
Dr. Mignot mignot{at}stanford.edu
Article usage
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg
► Watch
Related Articles
- No related articles found.